Prostate cancer risk and prognosis are adversely associated with a number of inflammatory and angiogenic mediators, including Toll‐like receptor 4 (TLR4), NF‐κB and VEGF 101, 102, 103, 104. Here, VEGFA is linked to prostate cancer.